Transgene

Transgene P/TBV

The Price to Tangible Book Value (P/TBV) of Transgene (TNG.PA) as of Nov 4, 2026 is 15.38. In the previous year, Price to Tangible Book Value (P/TBV) was 14.99 — a change of 2.58% (higher).

P/TBV

15.38

YoY

2.58%

Last updated:

Price to Tangible Book Value (P/TBV) of Transgene is 2024 15.38 . Price to Tangible Book Value (P/TBV) of Transgene was 2023 14.99 . It decreases by 2.58% higher compared to the previous year.

The Transgene P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2017
8.36 EUR
Jan 1, 2018
6.38 EUR
Jan 1, 2019
3.55 EUR
Jan 1, 2020
4.65 EUR
Jan 1, 2021
3.47 EUR
Jan 1, 2022
6.17 EUR
Jan 1, 2023
14.99 EUR
Jan 1, 2024
15.38 EUR
The Transgene P/TBV history
YEARP/TBVYoY
15.38+2.58%
14.99+143.14%
6.17+77.73%
3.47-25.34%
4.65+30.81%
3.55-44.29%
6.38-23.77%
8.36+65.52%
5.05-43.44%
8.93+171.59%
3.29—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Price to Tangible Book Value (P/TBV) of Transgene is 15.38 in 2024.

Price to Tangible Book Value (P/TBV) of Transgene changed from 14.99 to 15.38, representing a 2.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Transgene since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Transgene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Transgene

All Key Metrics — Transgene